Traws Pharma, Inc. (TRAW)

NCM – Real vaqt narxi. Valyuta: USD

1.68

-0.34 (-16.83%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.67

-0.01 (-0.61%)

Bozor oldidan: May 13, 2026, 6:10 AM EDT

08.05.2026

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.

08.05.2026

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.

08.05.2026

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to advance potential clinical candidates for the treatment of hantavirus infections.

20.04.2026

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

16.04.2026

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

15.04.2026

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,

19.02.2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID ® -ineligible patients, representing a significant population with no effective treatment options

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

15.04.2026

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,

19.02.2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

13.01.2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile

Traws Pharma, Inc. (TRAW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Traws Pharma, Inc. (TRAW)

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Videolar

No Data

Press-relizlar

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Videolar

No Data

Press-relizlar

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Search stocks

Traws Pharma, Inc. (TRAW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Traws Pharma, Inc. (TRAW)

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Videolar

No Data

Press-relizlar

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Videolar

No Data

Press-relizlar

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients